Cancer Patient Follow-up Exam Review

Flashcards covering CoC follow-up rates, registry processes, casefinding sources, death clearance, and recurrence coding based on final exam questions.

CoC 5-Year Follow-up Rate

A 90% rate must be maintained from the most current year of completed cases through five years before or the program's first accreditation date, whichever is shorter.

CoC 15-Year Follow-up Rate

An 80% rate must be maintained for all eligible cases from the most current year of completed cases through 15 years before or the program's first accreditation date.

Living Analytic Patient Follow-up Frequency

Follow-up information for each living analytic patient in CoC accredited facilities is obtained at least annually.

Follow-up List Generation Frequency

The process of generating a follow-up list should be completed monthly by a cancer registrar.

Lost to Follow-up (CoC)

A case is considered lost to follow-up if no information has been obtained within 15 months of the last contact date.

Non-analytic cases

Cases that are not submitted to the NCDB according to STORE (page 47).

NAACCR

The Standard Setter that publishes the EDITS metafile.

Date of First Recurrence Requirement

This date can only be recorded after a patient has a disease-free period.

Follow-up Process Step (Post-List Generation)

The registrar must look up each patient in the medical record for office visits or other information indicating disease progression or recurrence.

Reportable List

A list developed and maintained by each cancer program to guide identifying cases for inclusion in the cancer registry.

Primary Casefinding Sources

1. Pathology reports, 2. Medical/Radiation oncology logs and treatment summaries, and 3. HIM disease indices.

Disease Index (Primary Use)

The most important use of this tool is to identify cases not found through other means.

NCI SEER Casefinding List

A resource used by many registries to identify diagnostic codes to include in the disease index criteria.

Corrective Action Plan

A plan developed and executed if a program is not meeting the expected EPR of a CoC accountability or quality improvement measure.

CoC Measure Exemption

Programs with no cases eligible for assessment in a selected accountability or quality improvement measure are exempt from requirements for that measure.

Death Clearance Process

The process of matching registered deaths with reportable diseases already in the cancer registry.

Death Clearance Match

The step in the death clearance process where the mortality file from the vital statistics office is linked with the cancer registry to update existing records.

Death Clearance Follow-back

The investigation of cases that did not match the cancer registry to determine if a reportable case was missed.

Death Certificate Only (DCO) case

A case entered into the registry when a death clearance investigation yields no further information on a previously unreported reportable disease.

Type of First Recurrence Code 70

A code used to demonstrate that a patient has never been disease-free, such as cases of asymptomatic CLL or prostate cancer receiving no treatment.

Type of First Recurrence Code 22

A code used for a patient who was disease-free but then presented with a recurrence in a regional lymph node (e.g., metastatic infiltrating ductal carcinoma in an axillary node).

Type of First Recurrence Code 59

A code used for conditions like lymphoma or leukemia when they recur following a disease-free period.

Type of First Recurrence Code 06

A code used for in situ recurrences, such as additional bladder tumors identified as transitional cell carcinoma in situ.

Type of First Recurrence Code 54

A code used for metastatic recurrence (e.g., colon primary recurring as liver metastasis).

Type of First Recurrence Code 52

A code used for distant metastatic recurrence, such as pancreatic cancer recurring as lung lesions.

Cancer Status Code 1

A code used when a patient is disease-free or in remission.

Cancer Status Code 2

A code used when a patient has active disease (as seen initially in CLL patients or those with active metastatic lesions).